2-Year outcomes of dolutegravir plus lamivudine in ART-naive and pre-treated people living with HIV in Germany: Real-world Data From the URBAN Cohort

被引：0
|
作者：
Beer, Daniel [1 ]
Scherzer, Jenny [2 ]
Noe, Sebastian [3 ]
Scholten, Stefan [4 ]
Wyen, Christoph [5 ]
Postel, Nils [6 ]
Degen, Olaf [7 ]
Sabranski, Michael [8 ]
Westermayer, Bernd [9 ]
Dymek, Kathrin M. [2 ]
Baum, Alexander [2 ]
机构：
[1] IPZB Aachen Praxis Dr H Knechten, Aachen, Germany
[2] ViiV Healthcare, Munich, Germany
[3] MVZ Munchen Goethepl, Munich, Germany
[4] Praxis Hohenstaufenring, Cologne, Germany
[5] Praxis Ebertpl, Cologne, Germany
[6] Prinzmed, Munich, Germany
[7] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[8] ICH Study Ctr, Hamburg, Germany
[9] GSK, Munich, Germany
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
81003
引用
收藏
页码：28 / 30
页数：3
相关论文
共 39 条
  • [21] Effectiveness and tolerability of the two-drug regimen dolutegravir plus lamivudine in people with HIV-1: a systematic literature review of real-world evidence from clinical practice
    Letang, Emilio
    Priest, Julie
    Di Giambenedetto, Simona
    Monforte, Antonella d'Arminio
    Casado, Jose
    Cabello-Ubeda, Alfonso
    Hocqueloux, Laurent
    Allavena, Clotilde
    Barber, Tristan J.
    Jha, Diwakar
    Kamath, Rahul Dinesh
    Sithamparanathan, Myooran
    van Wyk, Jean
    Evitt, Lee
    HIV MEDICINE, 2022, 23 : 37 - 38
  • [22] Virological efficacy of dolutegravir plus darunavir in multi-drug-resistant HIV patients: a real-world cohort study with data from the PRESTIGIO registry
    Lagi, Filippo
    Bellomo, Michele
    Lolatto, Riccardo
    Ducci, Filippo
    Kiros, Seble Tekle
    Papaioannu, Rebecka
    Celemente, Tommaso
    Calza, Leonardo
    Feasi, Marcello
    Foca, Emanuele
    Giacomelli, Andrea
    Gulminetti, Roberto
    Menzaghi, Barbara
    Castagna, Antonella
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 127 - 128
  • [23] Dolutegravir plus lamivudine 2-drug regimen is highly effective and welltolerated in a real-world clinical setting in Europe: Data from the COMBINE-2 Study
    Mussini, C.
    Henegar, C.
    Assoumou, L.
    De Wit, S.
    Johnson, M.
    Roldan, E. Quiros
    Ragone, L.
    Jones, B.
    van Wyk, J.
    Aboud, M.
    Fletcher, C.
    Duffy, A.
    Bannoo, S.
    Pozniak, A.
    Vannappagari, V.
    HIV MEDICINE, 2023, 24 : 140 - 142
  • [24] 12-months outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected patients: real-world data from the German JUNGLE cohort
    Noe, S.
    Ummard-Berger, K.
    Hillenbrand, H.
    Beer, D.
    Wyen, C.
    Pauli, R.
    Postel, N.
    Dymek, K.
    Westermayer, B.
    Scherzer, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 44 - 45
  • [25] Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world Data
    Sakamoto, Yasutoshi
    Bando, Hideaki
    Nakamura, Yoshiaki
    Hasegawa, Hiromi
    Kuwaki, Takako
    Okamoto, Wataru
    Taniguchi, Hiroya
    Aoyagi, Yoshihiro
    Miki, Izumi
    Uchigata, Hiroshi
    Kuramoto, Naomi
    Fuse, Nozomu
    Yoshino, Takayuki
    Ohtsu, Atsushi
    CLINICAL COLORECTAL CANCER, 2023, 22 (01) : 45 - 52
  • [26] Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study
    Peichl, Peter
    Alten, Rieke
    Galeazzi, Mauro
    Lorenz, Hanns-Martin
    Nuesslein, Hubert
    Navarro, Federico
    Elbez, Yedid
    Chartier, Melanie
    Hackl, Roland
    Rauch, Christiane
    Connolly, Sean E.
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2020, 170 (5-6) : 132 - 140
  • [27] Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected Patients With High-Level Viral Load: Preliminary Data From the Real World
    Zhao, Fang
    Rao, Man
    Chen, Weimei
    Cai, Kanru
    Zhang, Lukun
    Xu, Liumei
    Sun, Liqing
    Liu, Xiaoning
    He, Yun
    Wang, Hui
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2022, 91 : S16 - S19
  • [28] Systematic literature review of real-world experience with the 2-drug regimen dolutegravir plus lamivudine (DTG+3TC) in people with HIV-1 (PWH) aged ≥50 years
    Letang, E.
    Di Giambenedetto, S.
    Monforte, A. d'Arminio
    Casado, J.
    Cabello-Ubeda, A.
    Hocqueloux, L.
    Allavena, C.
    Barber, T. J.
    Kabra, M.
    Priest, J.
    Clark, A.
    Jones, B.
    HIV MEDICINE, 2023, 24 : 135 - 137
  • [29] Providing evidence from real-world data - three-year follow-up of dolutegravir-based regimens in routine clinical care in Germany: the final analysis of the DOL-ART cohort
    Postel, N.
    Wyen, C.
    Hillenbrand, H.
    Lutz, T.
    Moll, A.
    Pauli, R.
    Sych, M.
    Westermayer, B.
    Lueftenegger, D.
    Walli, R.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [30] Treatment-emergent integrase strand transfer inhibitor (INSTI) resistance-associated mutations among people living with HIV-1 treated with dolutegravir (DTG) plus lamivudine (3TC) with pre-existing M184V/I from real-world and interventional studies
    Fox, Dainielle
    Blick, Gary
    Mesplede, Thibault
    Verdier, Gustavo
    Calderon, Monica
    Parry, Chris M.
    Grove, Richard
    Letang, Emilio
    Priest, Julie
    Jones, Bryn
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 291 - 292
1234